In one paragraphArticle in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Amol C ShettyInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0001-8790-7649 Jarey WangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0001-9038-4674 Philip A SuteraDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0002-4021-5909 Matthew P DeekDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.ORCID 0000-0002-5949-5058 Krishnan R PatelRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-2120-1939 James ProudfootVeracyte, San Diego, CA.
Elai DavicioniVeracyte, San Diego, CA.
Arif HussainDepartment of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD.ORCID 0000-0001-8485-4406 Paul NguyenDepartment of Radiation Oncology, Mass General Brigham, Boston, MA.
Christopher SweeneySouth Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-0398-6018 Ella BoytimMasonic Cancer Center, University of Minnesota, Minneapolis, MN.
Charles J RyanMemorial Sloan Kettering Cancer Center, New York, NY.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MWomen's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MResource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Luigi Marchionni · 2022 to 2026
$8.9MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MRochester Network Lead Academic Participating SiteUG1CA233230 · NCI · UNIVERSITY OF ROCHESTER · PI Paul M Barr · 2019 to 2026
$6.9MTraining Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8MNCTN LAPS at Johns HopkinsUG1CA233196 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEBORAH K ARMSTRONG, Julie Renee Brahmer · 2019 to 2026
$4.6MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA271540NCI NIH HHS R37 CA288972NCI NIH HHS T32 CA154274NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180868NCI NIH HHS U54 CA273956NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233196NCI NIH HHS UG1 CA233230NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233329
6 · The paper itselfAbstract
purposeA six-gene panel involved in androgen production, uptake, and conversion (APUC-6:
methodsTranscriptomic data from 160 patients in the phase III Eastern Cooperative Oncology Group-ACRIN E3805 CHAARTED trial were analyzed. Patients were stratified into four subgroups based on APUC-6 and androgen receptor (
resultsPatients with APUC-6-high/AR-low expression showed significantly improved ttCP (hazard ratio [HR], 0.43 [95% CI, 0.22 to 0.82];
conclusionAPUC-6 expression and
Indexed as
Biomarkers, TumorProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantSteroid IsomerasesAgedAndrogen AntagonistsDocetaxelHumansMaleMultienzyme ComplexesProgesterone ReductasePrognosisReceptors, Androgen3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseAndrogen AntagonistsBiomarkers, TumorDocetaxelMultienzyme ComplexesProgesterone ReductaseReceptors, AndrogenSteroid Isomerases
Identifiers
PMID42628007
PMCPMC13526273
What OpenQuestion holds
Textmetadata
Read underepoch 390